What will be the primary focus of the next major international STI health campaign by end of 2025?
HIV/AIDS • 25%
Genital Herpes • 25%
HPV • 25%
Other • 25%
Announcements from WHO or other international health organizations
Over 846 Million Adults Aged 15-49 Live with Genital Herpes, 42 Million New Cases Annually
Dec 11, 2024, 03:27 AM
A recent survey highlights the widespread prevalence of genital herpes among individuals aged 15 to 49. According to the World Health Organization (WHO), over 846 million adults globally within this age group are living with the infection, which equates to more than one in five people. Additionally, there are 42 million new cases of genital herpes recorded annually. The sexually transmitted infection, which currently has no cure, underscores the need for advancements in vaccine development to address this global health challenge. More than 840 million people under age 50 are affected worldwide.
View original story
Misinformation counteraction • 25%
Other • 25%
Healthcare infrastructure • 25%
Vaccine distribution • 25%
Treatment Access • 25%
Research and Development • 25%
Testing and Prevention • 25%
Public Awareness Campaigns • 25%
Access to Medication • 25%
Stigma and Discrimination • 25%
Ineffective Policies • 25%
Lack of Funding • 25%
Europe • 25%
Other • 25%
Africa • 25%
Asia • 25%
Other outcome • 25%
US declines participation • 25%
No new initiatives announced • 25%
US participates in new initiative • 25%
Government-led campaigns • 25%
NGO-led campaigns • 25%
Joint government and NGO campaigns • 25%
No campaigns • 25%
Diplomatic Relations • 25%
Financial Implications • 25%
Impact on Global Health • 25%
Other • 25%
Other • 25%
Increased CDC funding • 25%
New health partnerships • 25%
No significant changes • 25%
Conflict resolution • 25%
Global health • 25%
Human rights • 25%
Democracy promotion • 25%
Other outcomes • 25%
Reduced funding for specific programs • 25%
Reallocation of resources • 25%
No significant impact • 25%
Support for WHO's call • 25%
Condemnation of Israel • 25%
Direct intervention • 25%
No significant response • 25%
United States • 25%
United Kingdom • 25%
India • 25%
South Africa • 25%
Other • 25%
Moderna • 25%
GlaxoSmithKline • 25%
Pfizer • 25%